title: Feasibility of a PB CD34+ cell transplantation procedure using standard leukapheresis products in very small children.
abstract: To evaluate the feasibility and efficacy of CD34+ cell immunoselection from routine peripheral blood stem cell (PBSC) harvests in very small children a prospective study was performed in 15 children with advanced neuroblastoma weighing 20 kg or less. Products of two consecutive leukaphereses carried out on a COBE Spectra separator after G-CSF alone mobilization were pooled for immunoselection on Ceprate column. The median number of CD34+ cells and total CFU-GM collected were respectively 5.9 x 10(6)/kg (range 2.3-23.4) and 126.9 x 10(4)/kg (range 52.9-559.9). After separation the median number of CD34+ cells in the adsorbed fraction was 2.6 x 10(6)/kg (range 1-9.8) with a median purity of 54% (range 21-82) and a median of 95.7-fold (range 35-250) enrichment. Thirteen patients underwent autografts with CD34+ PBSCs after a busulfan 600 mg/m2 + melphalan 180 mg/m2 preparative regimen. The median number of days to achieve an absolute granulocyte count of 0.5 x 10(9)/l and a platelet count of 20 x 10(9)/l were respectively, 12 (range 10-24) and 35 (range 25-43). The median number of platelet transfusions was nine (range 2-15). We conclude that safe and effective immunoselection and transplantation of CD34+ PBSC can be accomplished in children with low body mass.
authors.affiliation: Unité Bioclinique de Prélèvement et de Traitement des Cellules Souches Hématopoïétiques et Secteur d'Etude en Hématopoïése, Service de Pédiatrie B CHU Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Berger
authors.forename: J
authors.initials: J
authors.lastname: Kanold
authors.forename: C
authors.initials: C
authors.lastname: Rapatel
authors.forename: L
authors.initials: L
authors.lastname: deLumley
authors.forename: P
authors.initials: P
authors.lastname: Lutz
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: J P
authors.initials: JP
authors.lastname: Vannier
authors.forename: F
authors.initials: F
authors.lastname: Mechinaud
authors.forename: C
authors.initials: C
authors.lastname: Bergeron
authors.forename: M
authors.initials: M
authors.lastname: Favrot
authors.forename: P
authors.initials: P
authors.lastname: Gembara
authors.forename: P
authors.initials: P
authors.lastname: Halle-Hauss
authors.forename: J
authors.initials: J
authors.lastname: Bonhomme
authors.forename: P
authors.initials: P
authors.lastname: Travade
authors.forename: F
authors.initials: F
authors.lastname: Deméocq
mesh_terms: D018952:Antigens, CD34; D001835:Body Weight; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007937:Leukapheresis; D008297:Male; D009447:Neuroblastoma / Q000628:therapy*
chemical_list: D018952:Antigens, CD34